These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 29884455)

  • 1. Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults.
    Pérez-Molina JA; Martínez E; Blasco AJ; Arribas JR; Domingo P; Iribarren JA; Knobel H; Lázaro P; López-Aldeguer J; Lozano F; Mariño A; Miró JM; Moreno S; Negredo E; Pulido F; Rubio R; Santos J; de la Torre J; Tuset M; von Wichmann MA; Gatell JM
    Enferm Infecc Microbiol Clin (Engl Ed); 2019 Mar; 37(3):151-159. PubMed ID: 29884455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Costs and cost-efficacy analysis of the 2017 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
    Rivero A; Pérez-Molina JA; Blasco AJ; Arribas JR; Asensi V; Crespo M; Domingo P; Iribarren JA; Lázaro P; López-Aldeguer J; Lozano F; Martínez E; Moreno S; Palacios R; Pineda JA; Pulido F; Rubio R; Santos J; de la Torre J; Tuset M; Gatell JM
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 May; 36(5):268-276. PubMed ID: 28532596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costs and cost-effectiveness analysis of 2015 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
    Berenguer J; Rivero A; Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; Lázaro P; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Tuset M; Gatell JM;
    Enferm Infecc Microbiol Clin; 2016; 34(6):361-71. PubMed ID: 26321131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Costs and cost-efficacy analysis of the 2014 GESIDA/Spanish National AIDS Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
    Blasco AJ; Llibre JM; Berenguer J; González-García J; Knobel H; Lozano F; Podzamczer D; Pulido F; Rivero A; Tuset M; Lázaro P; Gatell JM;
    Enferm Infecc Microbiol Clin; 2015 Mar; 33(3):156-65. PubMed ID: 25175171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs and cost-efficacy analysis of the 2016 GESIDA/Spanish AIDS National Plan recommended guidelines for initial antiretroviral therapy in HIV-infected adults.
    Rivero A; Pérez-Molina JA; Blasco AJ; Arribas JR; Crespo M; Domingo P; Estrada V; Iribarren JA; Knobel H; Lázaro P; López-Aldeguer J; Lozano F; Moreno S; Palacios R; Pineda JA; Pulido F; Rubio R; de la Torre J; Tuset M; Gatell JM
    Enferm Infecc Microbiol Clin; 2017 Feb; 35(2):88-99. PubMed ID: 27459919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Analysis of costs and cost-effectiveness of preferred GESIDA/National AIDS Plan regimens for initial antiretroviral therapy in human immunodeficiency virus infected adult patients in 2013].
    Blasco AJ; Llibre JM; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
    Enferm Infecc Microbiol Clin; 2013 Nov; 31(9):568-78. PubMed ID: 23969276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National Plan for AIDS for the initial antiretroviral therapy in adult human immunodeficiency virus (HIV) infected patients in 2012].
    Blasco AJ; Arribas JR; Boix V; Clotet B; Domingo P; González-García J; Knobel H; López JC; Llibre JM; Lozano F; Miró JM; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM;
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):283-93. PubMed ID: 22525829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with LPV/r+3TC for initial ART in HIV infected adults.
    Gatell JM; Arribas JR; Lázaro P; Blasco A
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19603. PubMed ID: 25394107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Costs and cost effectiveness analysis of preferred GESIDA regimens for initial antiretroviral therapy].
    Blasco AJ; Arribas JR; Clotet B; Domingo P; González-García J; López-Bernaldo JC; Llibre JM; Lozano F; Podzamczer D; Santamaría JM; Tuset M; Zamora L; Lázaro P; Gatell JM
    Enferm Infecc Microbiol Clin; 2011 Dec; 29(10):721-30. PubMed ID: 22014894
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost/efficacy analysis of preferred Spanish AIDS study group regimens and the dual therapy with lopinavir/ritonavir plus lamivudine for initial ART in HIV infected adults.
    Gatell Artigas JM; Arribas López JR; Lázaro Y de Mercado P; Blasco Bravo AJ
    Enferm Infecc Microbiol Clin; 2016; 34(7):427-30. PubMed ID: 25749416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and safety of first-line antiretroviral regimens in clinical practice: a multicentre cohort study.
    Alejos B; Suárez-García I; Rava M; Bautista-Hernández A; Gutierrez F; Dalmau D; Sagastagoitia I; Rivero A; Moreno S; Jarrín I;
    J Antimicrob Chemother; 2020 Oct; 75(10):3004-3014. PubMed ID: 32667674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic impact of optimising antiretroviral treatment in human immunodeficiency virus-infected adults with suppressed viral load in Spain, by implementing the grade A-1 evidence recommendations of the 2015 GESIDA/National AIDS Plan.
    Ribera E; Martínez-Sesmero JM; Sánchez-Rubio J; Rubio R; Pasquau J; Poveda JL; Pérez-Mitru A; Roldán C; Hernández-Novoa B
    Enferm Infecc Microbiol Clin (Engl Ed); 2018 Mar; 36(3):157-164. PubMed ID: 28109551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparing Real-World Healthcare Costs Associated with Single-Tablet Regimens for HIV-1: The 2-Drug Regimen Dolutegravir/Lamivudine vs. Standard 3- or 4-Drug Regimens.
    Priest J; Germain G; Laliberté F; Duh MS; Mahendran M; Fakih I; Oglesby A
    Infect Dis Ther; 2023 Aug; 12(8):2117-2133. PubMed ID: 37552426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of first-line antiretroviral regimens in the era of integrase inhibitors: a cohort of HIV-positive individuals in Spain, 2014-2015.
    Jarrin I; Suarez-Garcia I; Moreno C; Tasias M; Del Romero J; Palacios R; Peraire J; Gorgolas M; Moreno S;
    Antivir Ther; 2019; 24(3):167-175. PubMed ID: 30747107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [GeSIDA/National AIDS Plan: Consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (Updated January 2014)].
    ;
    Enferm Infecc Microbiol Clin; 2014; 32(7):446.e1-42. PubMed ID: 24953253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choice of the initial antiretroviral treatment for HIV-positive individuals in the era of integrase inhibitors.
    Alejos B; Suárez-García I; Bisbal O; Iribarren JA; Asensi V; Górgolas M; Muga R; Moreno S; Jarrín I;
    PLoS One; 2019; 14(8):e0221598. PubMed ID: 31449566
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-Effectiveness of Juluca for Human Immunodeficiency Virus Infection Treatment in Virologically Suppressed Adults in Taiwan.
    Anderson SJ; Hsu CY; Ou HT; Ko NY; Yang CT; Lopes S
    Value Health Reg Issues; 2021 May; 24():216-223. PubMed ID: 33857719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain.
    Moreno Guillen S; Losa García JE; Berenguer Berenguer J; Martínez Sesmero JM; Cenoz Gomis S; Graefenhain R; Lopez Sanchez-Cambronero D; Parrondo Garcia FJ
    Farm Hosp; 2017 Sep; 41(5):601-610. PubMed ID: 28847249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DOLAMA study: Effectiveness, safety and pharmacoeconomic analysis of dual therapy with dolutegravir and lamivudine in virologically suppressed HIV-1 patients.
    Hidalgo-Tenorio C; Cortés LL; Gutiérrez A; Santos J; Omar M; Gálvez C; Sequera S; Jesús SE; Téllez F; Fernández E; García C; Pasquau J
    Medicine (Baltimore); 2019 Aug; 98(32):e16813. PubMed ID: 31393412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Executive summary of the GeSIDA/National AIDS Plan consensus document on antiretroviral therapy in adults infected by the human immunodeficiency virus (updated January 2018).
    AIDS Study Group (GeSIDA) of the Spanish Society of Infectious Diseases and Clinical Microbiology and the National AIDS Plan:
    Enferm Infecc Microbiol Clin (Engl Ed); 2019 Mar; 37(3):195-202. PubMed ID: 29759422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.